Advertising
Showing 1 to 15 of 114 entries
BUY
Operates at almost 8% free cash flow yield. Pays a 3.7% yield.
0
COMMENT
Biotechs have strong balance sheets, better than a few years ago. Likes this as well as Amgen. Better to buy individual biotech stocks over ETFs. He has options calls on Abbvie.
0
BUY
Is an innovative pharma company. Life sciences companies are getting more interest from investors.
0
BUY
People want cash flow and now cash burn now. Biotech is bouncing like cryptos. You can buy this of IBB, but there are huge opportunities in biotech.
0
PAST TOP PICK
(A Top Pick Oct 20/20, Up 90%) Largest biotech company. Concerns about Humira coming off patent were overblown. Likes its R&D, as well as its M&A strategy. Missed on one trial, another one coming up. Good balance sheet, pretty good dividend, consistent cashflow. Good entry point.
0

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Apr 27/21, Up 34.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABBV has triggered its stop at $152. To remain disciplined we recommend covering the position at this time.
0
PARTIAL SELL
He trimmed his AbbVie to buy back Chipotle which he once owned. Though the near-term market direction is cloudy, he is seeking opportunity. He bought AbbVie last November at $115. Over three days, AbbVie jumped 8%, way faster than in recent years, but then it was wiped out in just three days. So, he sold half his position. He bought Chipotle, because he wanted growth at a reasonable valuation. It can endure theses inflationary times. Brand recognition helps. Fast food continues to sell.
0
SELL ON STRENGTH
Allan Tong’s Discover Picks Though shares are topping $175, AbbVie's PE of 25.1x is at its lowest in the past year, nearly 40x at the end of March 2021, for example. Then again, Merck trades at 18x and Pfizer 13.8x. The street remains confident in AbbVie, calling 11 buys and five holds, though the price target is $155.47, about $15 lower than current levels. AbbVie looks healthy for the long term, but it wouldn't hurt to bank a few profits while shares are riding high. Read 3 Promising Healthcare Stocks for our full analysis.
0
SELL
Major product, over 40% of revenues, is going off-patent next year, creating a higher risk profile. He sold. It has risen since then, but he doesn't like to be greedy, and he can sleep better. Sometimes it's time to move on. Wonderful profile, attractive dividend, attractive multiple, good growth rate, momentum.
0

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Apr 22/21, Up 47.9%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABBV is progressing well. We now recommend trailing up the stop (from $140) to $152.
0
BUY
He likes it. Pays a 3.5% dividend. They are presenting at several big medical conferences, so any good news could spike the stock.
0
BUY
She just trimmed her holding last week, because it's done very well. Their drug pipeline looks positive. Healthcare is her second-favourite sector and this is a great way to play it.
0
COMMENT
They have done well recently but he is looking for companies with longer term potential and expiry dates for drug patents. Should have good pipelines. Prefers diabetic care companies since this disease is on the rise. eg. Eli Lilly or Novo Nordisk. Astra Zeneca has a good pipeline in oncology drugs.
0
SELL
Great dividend, low valuation at 10x, and growing well, but he grabbed an exit point, as 43% of revenue comes from a drug going off patent next year. Pricing pressures mean that ABBV will see a decline in revenues and cashflows. Did well, but time to leave in favour of companies well off their highs.
0

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Apr 22/21, Up 32.6%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with ABBV is progressing well. To remain disciplined, we now recommend trailing up the stop (from $130) to $140.
0
Showing 1 to 15 of 114 entries

AbbVie Inc.(ABBV-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 25

Neutral - Hold Signals / Votes : 3

Bearish - Sell Signals / Votes : 5

Total Signals / Votes : 33

Stockchase rating for AbbVie Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

AbbVie Inc.(ABBV-N) Frequently Asked Questions

What is AbbVie Inc. stock symbol?

AbbVie Inc. is a American stock, trading under the symbol ABBV-N on the New York Stock Exchange (ABBV). It is usually referred to as NYSE:ABBV or ABBV-N

Is AbbVie Inc. a buy or a sell?

In the last year, 33 stock analysts published opinions about ABBV-N. 25 analysts recommended to BUY the stock. 5 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for AbbVie Inc..

Is AbbVie Inc. a good investment or a top pick?

AbbVie Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for AbbVie Inc..

Why is AbbVie Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is AbbVie Inc. worth watching?

33 stock analysts on Stockchase covered AbbVie Inc. In the last year. It is a trending stock that is worth watching.

What is AbbVie Inc. stock price?

On 2022-05-23, AbbVie Inc. (ABBV-N) stock closed at a price of $148.03.